---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-097739"
form_type: "8-K"
ticker: "TOVX"
cik: "0000894158"
company_name: "Theriva Biologics, Inc."
filed_at: "2025-10-08T23:59:59+00:00"
generated_at: "2026-05-17T04:23:09.469137+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Theriva Biologics unveils positive preclinical data for VCN-12, showing superiority over VCN-01

## Summary
- VCN-12 showed up to 13.7x greater cytotoxicity than VCN-01 across multiple cancer cell lines in vitro.
- In HP-1 pancreatic tumor hamster model, VCN-12 significantly reduced growth in both injected and non-injected tumors.
- Complete tumor regression in 2/9 hamsters; those animals rejected tumor re-challenge 43 days later.
- VCN-12 incorporates bee hyaluronidase (higher activity) and parasporin-2 to enhance immunogenic cell death.
- Toxicity profile in mice similar to VCN-01; further preclinical studies planned.

## SEC filing metadata
- accession: 0001104659-25-097739
- form_type: 8-K
- ticker: TOVX
- cik: 0000894158
- company_name: Theriva Biologics, Inc.
- filed_at: 2025-10-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/894158/000110465925097739/0001104659-25-097739-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/894158/000110465925097739/tm2528131d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-097739
- JSON: https://secwatch.observer/filing/0001104659-25-097739.json
- Plain text: https://secwatch.observer/filing/0001104659-25-097739.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.